Skip to main content
. 2020 Sep 18;4(12):1180–1187. doi: 10.1038/s41551-020-00611-x

Fig. 2. Profiling seroconversion in COVID-19.

Fig. 2

Simoa serological assay results for IgG, IgM and IgA against the four viral targets (spike, S1 subunit, RBD and nucleocapsid) for pre-pandemic samples (light blue; n = 200), nasopharyngeal (NP) PCR-negative samples (dark blue; n = 100) and SARS-CoV-2-positive samples (black (immunocompetent; n = 141) or red (immunosuppressed; n = 31)). The SARS-CoV-2-positive samples were divided into four groups according to time since since the first positive nasopharyngeal RT–PCR test. Black lines indicate the median normalized AEB value of each population.